Rare Disease Report

RNAi Explained - A Conversation with Alnylam President, Barry Greene

AUGUST 20, 2015
James Radke, PhD

Barry Greene, President and COO of Alnylam Pharmaceuticals explains the technology behind the RNA interference (RNAi) therapies that the company have in development.

For more information, visit www.alnylam.com/

Stay informed on the latest rare disease news and developments by signing up for our newsletter.
Copyright © RareDR 2013-2018 Rare Disease Communications. All Rights Reserved.